Results 101 to 110 of about 36,083 (204)

GPU-Accelerated Virtual Screening and Molecular Dynamics Simulations for Identification of Novel DPP‑4 Inhibitors. [PDF]

ACS Omega
Vasquez-Martínez N, Trapala J, Álvarez-Añorve LI, Lizárraga-Valadez RA, González-Andrade M, Sosa-Peinado A.   +5 more
europepmc   +1 more source

Concomitant Use of DPP-4 Inhibitors May Prevent the Development of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Cohort Study. [PDF]

Clin Transl Sci
Koura Y, Mine K, Fujita S, Kawashiri T, Mori Y, Ueda M, Kaneko R, Hirota T, Uchida M, Kobayashi D.   +9 more
europepmc   +1 more source

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. [PDF]

BMC Pharmacol Toxicol
Ramalingam PS, Hussain MS, Chellasamy G, Elangovan S, Sharma D, T P, Mishra RAK, Kodiveri Muthukaliannan G, Hussain T, Alrokayan S, Balakrishnan P, Mekala JR, Arumugam S.   +12 more
europepmc   +1 more source

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Kumari K, Bai A, Geeta F, Wadhwani N, Kumar R, Kumar A, Kumari R, Bai L, Muskan F, Kashish F, Yousafzai M.   +10 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naïve individuals with diabetes: A target trial emulation. [PDF]

Diabetes Obes Metab
Tatewaki T, Okada A, Kimura Y, Yasunaga H.   +3 more
europepmc   +1 more source

DPP-4 inhibitors for preventing post-stroke cognitive impairment in diabetic patients with acute ischemic stroke: a retrospective cohort study. [PDF]

Am J Transl Res
Fu H, Liu J, Wu J, Zou F.
europepmc   +1 more source

Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review. [PDF]

Diseases
Villa Chagas H, Laurindo LF, Dogani Rodrigues V, Haber JFDS, Chagas EFB, Barbalho SM.   +5 more
europepmc   +1 more source

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. [PDF]

Diabetes Res Clin Pract
Hong AT, Lin F, Luu IY, Shin L, Han SM, Armstrong DG, Tan TW.   +6 more
europepmc   +1 more source

Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials. [PDF]

Int J Mol Sci
Hung CM, Hsu CW, Zeng BS, Suen MW, Chen JJ, Zeng BY, Carvalho AF, Stubbs B, Chen YW, Chen TY, Hsu SP, Wang HY, Liang CS, Tu YK, Tseng PT.   +14 more
europepmc   +1 more source

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy. [PDF]

Biomedicines, 2023
Złotek M, Kurowska A, Herbet M, Piątkowska-Chmiel I.   +3 more
europepmc   +1 more source